Retinal Disease Clinical Trial
Official title:
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")
Verified date | December 2022 |
Source | Editas Medicine, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").
Status | Active, not recruiting |
Enrollment | 34 |
Est. completion date | May 23, 2025 |
Est. primary completion date | May 23, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years and older |
Eligibility | Inclusion Criteria: - Male or female - At least 3 years of age at screening with CEP290-related retinal degeneration caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in IVS26 of the CEP290 gene. - Visual Acuity: - Sentinel participant will have severe vision loss with a logMAR BCVA of =1.6 to 3.9 (20/800 or worse to LP) in the study eye - Non-sentinel participants must have BCVA between 1.0 - 3.0 logMAR in the study eye Exclusion Criteria: - Other known disease-causing mutations - Achieves a passing score for the mobility course at the most difficult level - In either eye, active systemic or ocular/intraocular infection or inflammation - In either eye, history of steroid-responsive intraocular pressure with increases > 25 mm Hg following corticosteroid exposure - Any vaccination/immunization in the last 28 days before screening - Inability or unwillingness to take oral prednisone - Prior gene therapy or oligonucleotide treatment |
Country | Name | City | State |
---|---|---|---|
United States | W.K. Kellogg Eye Center - University of Michigan | Ann Arbor | Michigan |
United States | Massachusetts Eye and Ear Infirmary | Boston | Massachusetts |
United States | Bascom Palmer Eye Institute | Miami | Florida |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Casey Eye Institute - OSHU | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Editas Medicine, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of Adverse Events related to EDIT-101 | 1 year | ||
Primary | Number of participants experiencing procedural related adverse events | 1 year | ||
Primary | Incidence of dose limiting toxicities | 1 year | ||
Secondary | Maximum tolerated dose as determined by occurrence of dose limiting toxicities | 1 year | ||
Secondary | Change from baseline in Mobility course score | Testing the subjects visual function by having the subject walk through obstacle courses. Courses will have different levels of difficulty depending on the light levels of the room and the contrast of the objects in the room. | 1 year | |
Secondary | Change from baseline in LogMAR measurement of BCVA | The test will evaluate visual acuity in ranges from light perception to normal vision. | 1 year | |
Secondary | Change from baseline in pupillary response | Measuring the change in pupil diameter in response to a light stimulus. | 1 year | |
Secondary | Change from baseline in dark adapted visual sensitivity using Full field light sensitivity threshold (FST) | Flashes of light of varying luminance are presented to the eye and the subject reports is the flash was seen. | 1 year | |
Secondary | Change from baseline in macula thickness | 1 year | ||
Secondary | Change from baseline in contrast sensitivity | The Lea symbols chart will be used for subjects under age 6 and the Pelli-Robson chart for all other subjects. The images or letters on the charts are in decreasing contrast. | 1 year | |
Secondary | Change from baseline in macular sensitivity as measured by microperimetry | Visual field test measuring the amount of light perceived in specific parts of the macula. | 1 year | |
Secondary | Change from baseline in color vision score using the Farnsworth 15 score | The Farnsworth D15 tests for congenital and acquired color vision defects. Fifteen color discs will be arranged by the subject. Scoring is accomplished by recording the sequence selected by the patient on a copy of the score sheet. A patient with a color vision deficiency will arrange the color discs in a different order than a person with normal color vision. | 1 year | |
Secondary | Change from baseline in QOL score for Age <8 years using the Children's Visual Function Questionnaire | 1 year | ||
Secondary | Change from baseline in QOL score for Age 8 to <18 years using the Impact of Vision Impairment for Children | 1 year | ||
Secondary | Change from baseline in QOL score for Age >18 years if BCVA is worse than 1.0 logMAR in both eyes using the Impact of Vision Impairment for Very Low Vision | 1 year | ||
Secondary | Change from baseline in QOL score for Age >18 years if BCVA is 1.0 logMAR or better in both eyes using the Impact of Vision Impairment | 1 year | ||
Secondary | Change from baseline in visual field using kinetic perimetry | Kinetic perimetry looks as the visual field to identify regions of normal and abnormal sensitivity to light | 1 year | |
Secondary | Change from baseline in Patient Global Impressions of Change score | This QOL has 5 non-numeric choices for the subject to select how they believe their condition has changed. | 1 year | |
Secondary | Change from baseline in gaze tracking | Video clips of the eyes are used to measure eye position and stability over time. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04956237 -
Retinal Surgery With or Without Anesthesiologist, Comparison of Surgeon and Patient's Comfort
|
||
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Active, not recruiting |
NCT04130841 -
Effects of Internal Limiting Membrane Peeling on Visual Function in Epiretinal Membrane Surgery
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Active, not recruiting |
NCT04636307 -
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
|
||
Not yet recruiting |
NCT06451068 -
Peripheral Retina Robotically Aligned OCT Study
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Completed |
NCT02315170 -
Assessment of Novel Intraocular Injection Guide
|
N/A | |
Completed |
NCT00069199 -
Optical Coherence Tomography Comparative Study
|
N/A | |
Withdrawn |
NCT03603990 -
Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema
|
N/A | |
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02445001 -
Erythrocyte Ghost Mediated Retinal Diagnosis
|
N/A | |
Completed |
NCT01468337 -
Topical Interferon Gamma-1b for Central Serous Chorioretinopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01227993 -
Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
|
Phase 1/Phase 2 | |
Completed |
NCT00792259 -
Topcon 3D OCT-1000 Optical Coherence Tomography System
|
||
Completed |
NCT00035906 -
Research Study in Patients With Persistent Macular Edema
|
Phase 2 | |
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Terminated |
NCT04110015 -
Assessment of Visual Function in Ophthalmic Disorders Using Virtual Visual Field Analysis
|
||
Recruiting |
NCT03592017 -
Performance of Long-wavelength Autofluorescence Imaging
|
N/A | |
Recruiting |
NCT03823092 -
Polarization Perception in Health and Disease. Testing a New Sight Test
|